Literature DB >> 27930961

Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system.

Jonathan C Guito1, César G Albariño1, Ayan K Chakrabarti1, Jonathan S Towner2.   

Abstract

Filoviruses are highly lethal in humans and nonhuman primates, likely due to potent antagonism of host interferon (IFN) responses early in infection. Filoviral protein VP35 is implicated as the major IFN induction antagonist, while Ebola virus (EBOV) VP24 or Marburg virus (MARV) VP40 are known to block downstream IFN signaling. Despite progress elucidating EBOV and MARV antagonist function, those for most other filoviruses, including Reston (RESTV), Sudan (SUDV), Taï Forest (TAFV), Bundibugyo (BDBV) and Ravn (RAVV) viruses, remain largely neglected. Thus, using standardized vectors and reporter assays, we characterized activities by each IFN antagonist from all known ebolavirus and marburgvirus species side-by-side. We uncover noncanonical suppression of IFN induction by ebolavirus VP24, differing potencies by MARV and RAVV proteins, and intriguingly, weaker antagonism by VP24 of RESTV. These underlying molecular explanations for differential virulence in humans could guide future investigations of more-neglected filoviruses as well as treatment and vaccine studies. Published by Elsevier Inc.

Entities:  

Keywords:  Ebolavirus; Filoviral interferon antagonists; Filoviruses; Innate immune response; Interferon pathway; Marburgvirus; Neglected pathogens; Viral immune evasion; Viral protein function; Virus-host interactions

Mesh:

Substances:

Year:  2016        PMID: 27930961     DOI: 10.1016/j.virol.2016.11.015

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Severity of Disease in Humanized Mice Infected With Ebola Virus or Reston Virus Is Associated With Magnitude of Early Viral Replication in Liver.

Authors:  Jessica R Spengler; Greg Saturday; Kerry J Lavender; Cynthia Martellaro; James G Keck; Stuart T Nichol; Christina F Spiropoulou; Heinz Feldmann; Joseph Prescott
Journal:  J Infect Dis       Date:  2017-12-27       Impact factor: 5.226

2.  Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.

Authors:  Judith Olejnik; Adriana Forero; Laure R Deflubé; Adam J Hume; Whitney A Manhart; Andrew Nishida; Andrea Marzi; Michael G Katze; Hideki Ebihara; Angela L Rasmussen; Elke Mühlberger
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

Review 3.  Filovirus Strategies to Escape Antiviral Responses.

Authors:  Judith Olejnik; Adam J Hume; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler; Elke Mühlberger
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 4.  Zoonotic and reverse zoonotic transmission of viruses between humans and pigs.

Authors:  Helena Aagaard Glud; Sophie George; Kerstin Skovgaard; Lars Erik Larsen
Journal:  APMIS       Date:  2021-10-18       Impact factor: 3.428

5.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

6.  Putative endogenous filovirus VP35-like protein potentially functions as an IFN antagonist but not a polymerase cofactor.

Authors:  Tatsunari Kondoh; Rashid Manzoor; Naganori Nao; Junki Maruyama; Wakako Furuyama; Hiroko Miyamoto; Asako Shigeno; Makoto Kuroda; Keita Matsuno; Daisuke Fujikura; Masahiro Kajihara; Reiko Yoshida; Manabu Igarashi; Ayato Takada
Journal:  PLoS One       Date:  2017-10-17       Impact factor: 3.240

7.  Insights into Reston virus spillovers and adaption from virus whole genome sequences.

Authors:  César G Albariño; Lisa Wiggleton Guerrero; Harley M Jenks; Ayan K Chakrabarti; Thomas G Ksiazek; Pierre E Rollin; Stuart T Nichol
Journal:  PLoS One       Date:  2017-05-25       Impact factor: 3.240

8.  Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses.

Authors:  Spencer W Stonier; Andrew S Herbert; Ana I Kuehne; Ariel Sobarzo; Polina Habibulin; Chen V Abramovitch Dahan; Rebekah M James; Moses Egesa; Stephen Cose; Julius Julian Lutwama; Leslie Lobel; John M Dye
Journal:  J Exp Med       Date:  2017-07-19       Impact factor: 14.307

Review 9.  Ebolaviruses: New roles for old proteins.

Authors:  Diego Cantoni; Jeremy S Rossman
Journal:  PLoS Negl Trop Dis       Date:  2018-05-03

10.  Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing.

Authors:  Punya Shrivastava-Ranjan; Mike Flint; Éric Bergeron; Anita K McElroy; Payel Chatterjee; César G Albariño; Stuart T Nichol; Christina F Spiropoulou
Journal:  MBio       Date:  2018-05-01       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.